NRAS and secondary neoplasm: In particular, rates of consistency in BRAF/NRAS mutations between primary and secondary tumors varied according to the anatomical sites of metastasis: 109/120 (91%; p = 0.1123), for metastases in lymph nodes; 37/40 (92.5%; p = 0.4316), for visceral metastases; 19/24 (79%; p = 0.0227), for brain metastatic lesions; 37/52 (71%; p = 0.0009), for skin secondaries (Table 4).